RxSight/RXST

$54.92

4.92%
-
1D1W1MYTD1YMAX

About RxSight

RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.

Ticker

RXST

Sector

Healthcare

Trading on

NASDAQ

Industry

Misc. Capital Goods

CEO

Ron Kurtz

Employees

374

Headquarters

Aliso viejo, United States

RxSight Metrics

BasicAdvanced
$1.91B
Market cap
-
P/E ratio
-$1.42
EPS
-
Beta
-
Dividend rate
$1.91B
$58.21
$17.00
405.64K
8.057
7.223
0.074
0.097
-29.22%
-38.85%
-33%
21.417
11.624
11.897
81.77%
40.04%
82.4%

What the Analysts think about RxSight

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
14.18% upside
High $65.00
Low $61.00
$54.92
Current price
$62.71
Average price target

RxSight Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-31.92% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$28.5M
28.96%
Net income
$-9.1M
-26.61%
Profit margin
-31.92%
-43.1%

RxSight Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 28.21%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.42
-$0.40
-$0.35
-$0.26
-
Expected
-$0.53
-$0.47
-$0.43
-$0.36
-$0.27
Surprise
-20.83%
-14.89%
-19.23%
-28.21%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for RxSight stock?

RxSight (RXST) has a market cap of $1.91B as of April 24, 2024.

What is the P/E ratio for RxSight stock?

The price to earnings (P/E) ratio for RxSight (RXST) stock is 0 as of April 24, 2024.

Does RxSight stock pay dividends?

No, RxSight (RXST) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next RxSight dividend payment date?

RxSight (RXST) stock does not pay dividends to its shareholders.

What is the beta indicator for RxSight?

RxSight (RXST) does not currently have a Beta indicator.

What is the RxSight stock price target?

The target price for RxSight (RXST) stock is $62.71, which is 14.18% above the current price of $54.92. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell RxSight stock

Buy or sell RxSight stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing